This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| France Biobanque | |
|---|---|
| Name | France Biobanque |
| Formation | 2000s |
| Type | Biobank network |
| Headquarters | Paris |
| Region served | France |
France Biobanque
France Biobanque is a national network of human biological resource centers based in Paris, coordinating sample collection, processing, storage, and distribution for biomedical research across France. It interfaces with international initiatives such as BBMRI-ERIC, European Commission, World Health Organization, United States National Institutes of Health, and collaborates with universities and hospitals including Sorbonne University, Université de Paris, Hôpital Pitié-Salpêtrière, and Assistance Publique–Hôpitaux de Paris. The network supports translational programs linked to consortia like Human Genome Project, International HapMap Project, 1000 Genomes Project, and disease-specific efforts such as Cancer Research UK, Institut Curie, INSERM, and Institut Pasteur.
France Biobanque operates as a distributed infrastructure integrating regional biobanks located in centers such as Lille, Lyon, Marseille, Bordeaux, Toulouse, and Nantes. It provides biospecimens — e.g., blood, plasma, serum, DNA, RNA, tissue, and metadata — to investigators at institutions like Centre National de la Recherche Scientifique, CNRS, Collège de France, and clinical networks including Réseau National de Cancérologie. The system harmonizes standards with organizations such as International Society for Biological and Environmental Repositories, OECD, European Bioinformatics Institute, and links to data portals like ELIXIR.
The initiative grew from early biobanking projects supported by agencies such as Agence Nationale de la Recherche and programs under Ministry of Health (France), following examples like UK Biobank, Kaiser Permanente Research Bank, Framingham Heart Study, and cohort efforts including EPIC, Nurses' Health Study, and Avon Longitudinal Study of Parents and Children. Key milestones involved partnerships with academic hospitals including Hôpital Necker-Enfants Malades, Hôpital Saint-Louis, scientific organizations such as Inserm, and policy guidance from entities like Haute Autorité de Santé and Comité Consultatif National d'Éthique. Major projects linked to the network referenced protocols from European Research Council, Horizon 2020, and collaborations with industry partners including Sanofi, GlaxoSmithKline, Roche, Novartis, and Pfizer.
Governance frameworks draw on models from BBMRI-ERIC and national oversight by bodies such as Agence de la biomédecine, Ministry of Research (France), and advisory committees resembling Comité consultatif national d'éthique pour les sciences de la vie et de la santé. Funding streams include public grants from ANR, support from regional councils like Île-de-France Regional Council, and contracts with pharmaceutical corporations such as AstraZeneca and Bristol Myers Squibb. Institutional stakeholders include CHU de Bordeaux, CHU de Grenoble, AP-HP, and university partners like Université Claude Bernard Lyon 1.
Collections encompass biospecimens used in studies akin to PROTECT (study), EPIC, and biorepositories used by European Prospective Investigation into Cancer and Nutrition, offering sample types such as whole blood, peripheral blood mononuclear cells, formalin-fixed paraffin-embedded tissue, fresh frozen tissue, urine, saliva, cerebrospinal fluid, and derived materials like extracted nucleic acids and cell lines. Donor cohorts reflect recruitment settings including Institut Gustave Roussy, Hôpital Tenon, and population studies resembling CONSTANCES cohort and ELFE cohort. Metadata associated with specimens are harmonized with terminologies promoted by International Classification of Diseases, SNOMED CT, and data standards from HL7 and Clinical Data Interchange Standards Consortium.
Operational procedures mirror accreditation schemes from ISO 9001, ISO 20387, and quality systems used by College of American Pathologists and European Medicines Agency. Standard operating procedures cover cold chain logistics with equipment from suppliers partnering with Thermo Fisher Scientific, inventory management via laboratory information management systems similar to OpenSpecimen, and validation following guidelines from Good Clinical Practice and Good Laboratory Practice. Biobank units engage in proficiency testing and audits by organizations like AFNOR and networks such as European Biobanking and BioMolecular Resources Research Infrastructure.
Research enabled by the network spans molecular epidemiology, translational oncology, precision medicine, and population genetics in partnerships with Institut National du Cancer, CNRS, INSERM, Institut Pasteur, and industry collaborators including Sanofi and Roche Diagnostics. Collaborative studies connect to international projects like GenomeAsia 100K, Pan-Cancer Analysis of Whole Genomes, International Cancer Genome Consortium, All of Us Research Program, and regional cohorts such as EPIC-Norfolk. Data sharing aligns with initiatives like Global Alliance for Genomics and Health and repositories such as European Genome-phenome Archive.
Ethical oversight involves committees akin to Comité de Protection des Personnes, regulatory frameworks from Agence de la biomédecine, and legal instruments including aspects of French Civil Code and EU regulations like General Data Protection Regulation. Consent models reference instruments used in databases like dbGaP and policy discussions from Nuffield Council on Bioethics and Council of Europe conventions. Privacy-preserving measures leverage de-identification standards promoted by ISO and data governance frameworks similar to Data Use Ontology and agreements modeled on Material Transfer Agreement templates used by institutions such as Wellcome Trust.
Category:Biobanks